65,437 trials
Common Variable Immunodeficiency · X-linked Agammaglobulinemia · Autosomal Recessive Agammaglobulinemia
Primary: Total Serum IgG Trough Levels — 8.10; 7.49 g/L
Parkinson's Disease
Primary: Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living [ADL]) Score From Baseline to Month 3 — -2.5; -0.5 Units on a scale
Pregnancy - Labor Monitoring
Primary: Comparison of SureCALL® and TOCO Detection of Contraction Events, as Compared to the IUPC — -0.73; -1.74 Seconds — p=.04627
Vision Disorders
Primary: Distance Visual Acuity (VA) Between Test and Control Lenses Worse Than 20/40. — 2; 0 eyes
Neoplasms, Uterine Cervix · Metastatic Cervical Cancer
Primary: Progression-free Survival (PFS) in Interim Analysis — 12.6; 12.6; 17.9 Weeks — p=0.535
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 11.0; 8.3 months
Presbyopia
Primary: Overall Satisfaction With the Lenses — 82.5; 64.4 Units on a Scale
Metastatic Breast Cancer
Primary: Overall Survival — 29.2; 16.3 months — p=0.3348
Postoperative Pain
Primary: Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Hydromorphone: Clearance (Cl) — 114 L/hour
Alzheimer's Disease
Primary: Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study — 74.2 Percentage of participants
Organ Transplantation, Renal Transplantation
Primary: Renal Function Measured by Calculated Glomerular Filtration Rate (GFR Calculated According to the Nankivell Formula) — 68.5; 69.2; 63.6; 68.3 mL/min per 1.73 m^2
Cystic Fibrosis
Primary: Time to Need for Inhaled or Intravenous (IV) Antipseudomonal Antibiotics — 71; 92 Days — p=0.0070
Heart Defects, Congenital
Primary: Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)…
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
Acne Vulgaris
Primary: Change From Baseline in Total Non-inflammatory Lesion Count — -19.9; -9.7 Lesions